# Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

> **NCT03068351** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 24 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** RO6870810
- **BIOLOGICAL:** daratumumab

## Key facts

- **NCT ID:** NCT03068351
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-26
- **Primary completion:** 2019-08-01
- **Final completion:** 2019-08-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03068351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03068351, "Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03068351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*